Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 6Active not recruiting 5Not yet recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1

Conditions

TP53 Y220C Mutation 1Meningioma 1Medulloblastoma 1Localized Prostate Cancer 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Deglutition Disorders 1Cognitive Dysfunction 1

Interventions

Specimen Handling 313Magnetic Resonance Spectroscopy 272pembrolizumab 263Carboplatin 190Cyclophosphamide 177Biopsy 177Cisplatin 165Paclitaxel 137Gemcitabine 137Bevacizumab 122fludarabine 115Nivolumab 114Radiotherapy 111venetoclax 98Oxaliplatin 97Fluorouracil 87Docetaxel 85Dexamethasone 83Capecitabine 83Pemetrexed 76Drug Therapy 76Rituximab 75Leucovorin 71durvalumab 70Radiosurgery 67Doxorubicin 64Blood Specimen Collection 64Standard of Care 63Injections 62atezolizumab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Tablets × 90 days × Clear all
NCT06275919 2026-05-13

MIRAGE

Istituto Oncologico Veneto IRCCS

Phase 2 Recruiting
104 enrolled
CNS

Meningioma

NCT05907057 2026-05-08

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Servier

Phase 3 Recruiting
245 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05230758 2026-05-01

Met Med Can

The Hospital for Sick Children

Phase 3 Recruiting
140 enrolled
CNS

Medulloblastoma, Cognitive Dysfunction

NCT06966778 2026-03-16

Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial

National Taiwan University Hospital

Phase NA Recruiting
135 enrolled
Genitourinary

Localized Prostate Cancer

NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

NCT07217938 2026-03-03

TRADstat

Peter MacCallum Cancer Centre, Australia

Phase 2 Recruiting
48 enrolled
Head & Neck

Deglutition Disorders, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡